Pfizer (PFE) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pfizer (PFE) PT Lifted to $41 at BMO Capital on Sum-of-the-Parts
July 29, 2015 7:30 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Pfizer (NYSE: PFE) to $41.00 (from $39.00) following Q2 results, saying the sum of the parts is looking better and said a split is becoming more likely.
Arfaei commented, "Now $41/share based on the weighted average of DCF ($37,... More
